UNSPSC 51263010: Terazosin hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H25N5O4.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D32S14F082, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine but more generally known as terazosin hydrochloride, which bears US NIH Compound Identifier 5401. European Medicines Agency schedules Terazosin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04722MIG.

UNSPSC 51263010 Terazosin hydrochloride is a Commodity code that represents a specific pharmaceutical product — an alpha-1 adrenergic receptor antagonist used to treat hypertension and benign prostatic hyperplasia. However, the recent state and local opportunities posted under this code show a substantial mismatch: the single recent solicitation tracked involves naloxone and drug deactivation systems for community health purposes, not terazosin. This divergence suggests either a coding error in the source data or that the code is not being applied consistently to the pharmaceutical products its name describes.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 (with a response deadline of July 26, 2023, indicating a data timestamp inconsistency in the source), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford. The procurement involves competitive sealed bidding, e-procurement portal submission, E-Verify compliance, and a two-year initial term with a one-year renewal option. The contract is potentially FEMA-funded and includes standard insurance and drug-free workplace requirements. No recent opportunities specifically targeting terazosin hydrochloride procurement by state and local governments appear in the available data, making this code appear largely inactive for its nominal pharmaceutical scope among state and local buyers.